Can LPA variants like rs3798220 genetically raise lipoprotein(a)?

The rs3798220 (Ile4399Met) variant in the LPA gene is a powerful, genetically determined driver of elevated circulating lipoprotein(a) [Lp(a)] levels, directly influencing atherosclerotic cardiovascular disease (ASCVD) risk.

Genetic regulation and synthesis

• Dose-dependent elevation: Carrying the minor C risk allele of rs3798220 increases circulating Lp(a) concentrations by approximately 100 nmol/L per allele, translating to a 2- to 3-fold increase in plasma concentrations.
• Shorter isoforms: This variant is genetically linked to the expression of shorter apolipoprotein(a) isoforms with fewer kringle IV type 2 (KIV-2) repeats. Shorter isoforms undergo accelerated hepatic synthesis and secretion, leading to markedly elevated circulating levels.

Pathogenic mechanisms and structure

• Receptor clearance hindrance: Lp(a) consists of an apolipoprotein B-100 (ApoB) core covalently bound to apolipoprotein(a). The physical bulk of apolipoprotein(a) near the LDL receptor-binding region of ApoB-100 interferes with cellular receptor-mediated clearance, extending the particle's plasma residence time and increasing arterial wall retention.
• Impaired fibrinolysis: Because apolipoprotein(a) shares high structural homology with plasminogen, it competes for plasminogen-binding sites. This blocks normal clot breakdown (fibrinolysis), promoting a prothrombotic state.

Clinical cardiovascular risk

• Causal independent risk: Genetic Mendelian randomization studies establish that these ApoB-containing Lp(a) particles are independent, causal risk factors for coronary artery disease. This atherogenic risk remains highly significant even after adjusting for traditional LDL-C or overall ApoB levels.

Bottom line

• Bottom line: The rs3798220 variant genetically drives highly elevated Lp(a) levels by encoding smaller, rapidly synthesized isoforms. Because Lp(a) combines the atherogenicity of an ApoB-containing LDL core with the antifibrinolytic properties of apolipoprotein(a), it represents a potent, causally established mediator of cardiovascular risk.